GlassScriptPhysician profile
Yogender P Garg
NPI 1508870700
$11,108.07
in general payments reported to CMS, 2019-2025
32 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,304 · 2020: $502 · 2021: $1,153 · 2022: $1,528 · 2023: $1,869 · 2024: $1,875 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,621.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,542.22 | 2019-2025 | Rocklatan, Clareon, Argos |
| Abbvie INC. | $1,772.53 | 2022-2025 | |
| Allergan, INC. | $1,033.08 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $822.39 | 2019-2025 | Eylea Hd, Eylea |
| Glaukos Corporation | $746.96 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Nova Eye, INC. | $536.94 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $429.67 | 2019-2023 | Cequa |
| Bausch & Lomb Americas INC. | $348.50 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Vyzulta |
| Genentech USA, INC. | $304.33 | 2019-2024 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $274.58 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $265.79 | 2019-2021 | |
| Ellexiscience | $234.70 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $225.34 | 2019-2025 | Tecnis Iol, Lipiflow System Activator (Disposable) |
| Kala Pharmaceuticals, INC. | $202.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $185.39 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $145.04 | 2019 | |
| Astellas Pharma US INC | $140.50 | 2023-2025 | Izervay |
| Amgen INC. | $126.43 | 2025 | Tepezza |
| Rxsight INC | $124.78 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sight Sciences, INC. | $116.87 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $87.50 | 2022 | |
| Akorn, INC. | $84.86 | 2019-2020 | |
| Harrow Eye, LLC | $61.50 | 2025 | Iheezo |
| Thea Pharma INC. | $61.42 | 2022-2025 | Iyuzeh |
| Optos, INC. | $57.97 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $44.44 | 2023 | Syfovre |
| Oyster Point Pharma, INC. | $32.08 | 2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $25.94 | 2025 | Xdemvy |
| Quidel Corporation | $19.67 | 2020 | |
| Akorn Operating Company LLC | $18.89 | 2021 | |
| Ocular Therapeutix, INC. | $18.66 | 2021 | |
| Shire North American Group INC | $16.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yogender Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.